TYK2/JAK1 in Dermato? Interesting pre-clinical study of brepocitinib... but we really just need clinical data Glad to see this is headed straight to a Phase 3! Hoping they allow IVIG: has been a problem with many/most/all? recent dermato studies #ACR24 @RheumNow Abstr#0882 https://t.co/KS8fTMBpPR

• https://x.com/EBRheum/status/1858187090082800118/photo/1

Kharouf et al. Secondary biologic failure in PsA common - 36% over 5 years. Predictors - higher baseline SJC HR 1.39 and PASI HR 1.14. TNFi did better, HR 0.40, esp golimumab - but ?this as often used as first bDMARD? @RheumNow #ACR24 Abstr#1455 https://t.co/ET0WX6tKMr https://t.co/iVcCkM0hu3

• Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients w…
• https://x.com/RichardPAConway/status/1858187341455573295/photo/1

In this large 🇦🇺 RA cohort, median time on treatment for upadacitinib was lot higher than other JAKi (28mo vs 17mo) Why? Patient selection, or a real difference between JAKi? Would really like more comparative effectiveness data between JAKi #ACR24 OPAL group ABST1370 @RheumNow https://t.co/OU2ayzqIc8

• https://x.com/drdavidliew/status/1858188438056653021/photo/1

Spicy network SRMA, 123pts w/JAK-TNF-PLBO TNF >> JAK w/respect to malignancy (expected) & better than PLBO (spicy!) JAK > PLBO for heme cancers (makes sense); no significant (but slight trend) toward PLBO > JAK for all cancer The debate continues #ACR24 @RheumNow Abstr#0989 https://t.co/tBnb02gyzF

• https://x.com/EBRheum/status/1858188599910703531/photo/1

Brenac et al. Orbital MRI to distinguish GCA AOIN/CRO from non-arteritic. @RheumNow #ACR24 Abstr#1641 https://t.co/qIwaX3qp02 https://t.co/5CIZ0aV98Z

• Orbital MRI as a Promising Approach for the Diagnosis of Giant Cell Arteritis i…
• https://x.com/RichardPAConway/status/1858189606895940034/photo/1

Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter? in the upadacitinib ph3 trials, high disease activity pts had more: serious infections HZ MACE VTE Active RA is a massive contributor to many AEs in JAKi pts #ACR24 ABST1393 @RheumNow https://t.co/DlFf9Sfbja

• https://x.com/drdavidliew/status/1858190305398497317/photo/1

Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy

• Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab vers…
• https://x.com/RichardPAConway/status/1858190864708780251/photo/1

Harkins @DrTrishHarkins et al. PROs predict relapse in PMR. pVAS, HAQ health status, FACIT-F all positive predictors. Interestingly PHQ-9 negative predictor. @RheumNow #ACR24 Abstr#1238 https://t.co/kj4WgmI0oq https://t.co/xLDzRZvxoA

• Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in …
• https://x.com/RichardPAConway/status/1858191116337590456/photo/1

Gottlieb et al. TYK2i Zasocitinib in PsA. 12 week phase 2 RCT. Skin responses and MDA all favour zasocitinib but maybe not fantastic? PASI75 46%, PASI90 37%, PASI100 26%. MDA in photo. @RheumNow #ACR24 Abstr#1477 https://t.co/iX5iriESV2 https://t.co/RkEmcAZ80x

• Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibit…
• https://x.com/RichardPAConway/status/1858192626425749820/photo/1

Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/YvQnmmvNjF https://t.co/crYUwHahDb

• Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Di…
• https://x.com/RichardPAConway/status/1858183818525753664/photo/1

The idea of patient-initiated follow-up for RA is enticing: patient & physician time is already stretched minimize unnecessary visits/improve access but what actually needs to go into the design, to make it safe/workable? A: plenty. 🇨🇦 pilot underway #ACR24 ABST1041 @RheumNow https://t.co/03u4bhnQ0v

• https://x.com/drdavidliew/status/1858184151306047682/photo/1

STAR trial of GC w/d in RA LDA SEMIRA of GC w/d controlled RA on Toci Very slight disease activity increase, but higher flares No symptomatic adrenal insufficiency, but data of abnormal ACTH stim No good evidence of steroid w/d symptoms Beth Wallace @RheumNow #ACR24 https://t.co/j6UPWlVNIu

• https://x.com/ericdeinmd/status/1858185033858593232/photo/1
• https://x.com/ericdeinmd/status/1858185033858593232/photo/1
• https://x.com/ericdeinmd/status/1858185033858593232/photo/1

Slick poster, but must be careful w/real world data. Big risk of confounding/channeling bias Pts with MACE risk (not always well-characterized by ICD codes) also less likely to receive JAK & therefore less liekly to have subsequent MACE #ACR24 @RheumNow Abstr#1394 https://t.co/lilU0byJ1s

• https://x.com/EBRheum/status/1858185076560830717/photo/1

Zhou et al. Phase 2 RCT of XKH004, IL17A/Fi in AxSpA. ASAS40 50.4% vs 25%. Slightly odd dose response variation, but maybe just noise. @RheumNow #ACR24 Abstr#1453 https://t.co/SsTSThFzro https://t.co/C9yK2G4tqB

• Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal…
• https://x.com/RichardPAConway/status/1858185580116328614/photo/1

Getting more data on using deucravacitinib for PsO/PsA manifestations Impressive effect on scalp psoriasis (which often means a lot to patients) Given how safe it is, it's increasingly tempting to use more of it in mild-mod PsA #ACR24 PSORIATYK SCALP trial ABST1137 @RheumNow https://t.co/vxS3RSlIN0

• https://x.com/drdavidliew/status/1858185727491919901/photo/1